Mayne Pharma Group Limited
MAYNFOTCHealthcare● Active
$1.55
$-0.05(-3.13%)
Market Cap$125931032
P/E Ratio—
52W High$4
52W Low$1.4
Mayne Pharma Group Limited (MAYNF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MAYNF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-06 | 2024-06 | 2023-06 | 2022-06 | 2021-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.41B | $0.39B | $0.18B | $0.16B | $0.40B |
| Cost of Revenue | $0.16B | $0.17B | $0.16B | $0.25B | $0.21B |
| Gross Profit | $0.25B | $0.22B | $0.03B | $0.17B | $0.19B |
| Gross Margin %(computed) | 60.59% | 56.30% | 14.62% | 108.27% | 48.65% |
| Operating Expenses | |||||
| R&D Expenses | $0.02B | $0.02B | $0.02B | $0.03B | $0.05B |
| G&A Expenses | $0.11B | $0.06B | $0.06B | ($0.03B) | $0.03B |
| Total Operating Expenses | $0.27B | $0.36B | $0.21B | $0.21B | $0.19B |
| Operating Income | ($0.02B) | ($0.14B) | ($0.19B) | ($0.14B) | ($0.04B) |
| Operating Margin %(computed) | -5.78% | -35.83% | -101.56% | -86.29% | -9.12% |
| Interest Income | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.03B | $0.03B | $0.01B | $0.03B | $0.03B |
| Income Before Tax | ($0.08B) | ($0.19B) | ($0.27B) | ($0.15B) | ($0.26B) |
| Income Tax Expense | $0.01B | ($0.02B) | $0.05B | $0.07B | ($0.05B) |
| Net Income | ($0.09B) | ($0.17B) | $0.12B | ($0.21B) | ($0.21B) |
| Net Margin %(computed) | -22.99% | -44.89% | 63.87% | -133.30% | -52.06% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.14 | $-2.12 | $-3.85 | $-3.20 | $-2.65 |
| Wtd Avg Shares | 0.08B | 0.08B | 0.08B | 0.08B | 0.08B |
| EBITDA | $0.04B | ($0.09B) | ($0.17B) | ($0.05B) | $0.05B |
| EBITDA Margin %(computed) | 10.31% | -22.45% | -95.00% | -29.49% | 12.50% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · AUD · B
Explore more Mayne Pharma Group Limited data
About Mayne Pharma Group Limited (MAYNF) Income Statement
Mayne Pharma Group Limited (MAYNF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MAYNF reported revenue of $0.41B, gross profit of $0.25B (gross margin 60.59%), and net income of ($0.09B) — a net profit margin of -22.99%.
Frequently asked questions
MAYNF · 4 questionsMayne Pharma Group Limited (MAYNF) reported revenue of $0.41B for 2025, up 5.1% year-over-year.
MAYNF revenueMAYNF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09